Home » Topics » Regulatory » EMA

EMA
RSS

Bristol-Myers Squibb's Yervoy recommended for approval in Europe for pediatric melanoma

Dec. 19, 2017

EMA committee recommends approval of Alkindi for pediatric adrenal insufficiency

Dec. 18, 2017

EMA committee recommends approval of Ozempic for type 2 diabetes

Dec. 18, 2017

Celltrion's trastuzumab biosimilar recommended for E.U. approval

Dec. 18, 2017

EMA committee hands down positive opinion on burosumab for X-linked hypophosphatemia

Dec. 18, 2017

CHMP grants positive opinion to Cx601 for the treatment of perianal fistulas in Crohn's disease

Dec. 18, 2017

EMA's CHMP requests additional information for betrixaban MAA

Dec. 13, 2017

EMA validates application for Opdivo plus Yervoy in advanced renal cell carcinoma

Dec. 1, 2017

EMA gives orphan drug designation to ProQR Therapeutics' QR-313

Nov. 30, 2017

EMA grants orphan drug designation for DCC-2618 as treatment of gastrointestinal stromal tumors

Nov. 30, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 9, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 3, 2026